<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01002534</url>
  </required_header>
  <id_info>
    <org_study_id>VARD-99</org_study_id>
    <nct_id>NCT01002534</nct_id>
  </id_info>
  <brief_title>Does a Nasal Instillation of Vardenafil Normalize the Nasal Potential Difference in Cystic Fibrosis Patients?</brief_title>
  <official_title>Does a Nasal Instillation of Vardenafil Normalize the Nasal Potential Difference in Cystic Fibrosis Patients Homozygous for the F508del Mutation? A Randomized, Double Blind, Placebo-controlled Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cliniques universitaires Saint-Luc- Université Catholique de Louvain</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cliniques universitaires Saint-Luc- Université Catholique de Louvain</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the effect of a nasal instillation of Vardenafil
      on nasal potential difference in cystic fibrosis patients homozygous for the F508del mutation
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      CFTR protein has been shown to be an ohmic, small conductance channel regulated by cAMP
      intracellular levels that are balanced by degradation through cyclic nucleotide
      phosphodiesterases (PDE). Several families of PDEs with varying selectivities for cAMP and/or
      cGMP have been identified.PDE5 is highly specific for cGMP and is involved in the regulation
      of the intracellular concentration of cGMP in various tissues. Recently, it has been shown,
      in a preclinical model of transgenic mice, that pharmacological doses of sildenafil and
      vardenafil, two clinically approved PDE5 inhibitors, stimulate chloride transport activity of
      the mutant F508del-protein (Lubamba et al, 2008); this parameter has been assessed by means
      of the nasal potential difference (NPD). An increasing effect of sildenafil on the expression
      of F508del-CFTR protein (Dormer et al,2005) was originally reported in nasal epithelial cells
      harvested from patients with cystic fibrosis and cultured on impermeable supports, a
      configuration that allows interaction of drugs with the apical side of epithelia.

      This study aims at investigating the effect of a single local administration of vardenafil on
      NPD measurements in CF patients homozygous for the F508del mutation.
    </textblock>
  </detailed_description>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    not yet started
  </why_stopped>
  <start_date>October 2011</start_date>
  <completion_date type="Anticipated">June 2012</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cumulated changes in response to Chloride-free solution and isoproterenol (reflecting chloride transport)</measure>
    <time_frame>Change from baseline (visit 1) and placebo to Vardenafil instillation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in basal voltage value and in amiloride response (reflecting sodium transport)</measure>
    <time_frame>Change from baseline (visit1) and placebo to Vardenafil instillation</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Cystic Fibrosis</condition>
  <arm_group>
    <arm_group_label>baseline</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>visit 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vardenafil</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>nasal instillation of Vardenafil ( visit 2 or 3)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Nasal instillation of placebo (visit 3 or 2)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vardenafil</intervention_name>
    <description>Nasal instillation of Vardenafil</description>
    <arm_group_label>Vardenafil</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Nasal instillation of placebo matching in appearance with the Vardenafil instillation</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Cystic fibrosis patients homozygous for the F508del mutation as confirmed by a genetic
             test

          -  Aged 14 years and older

          -  Male and female

          -  FEV1 &gt;50% of predicted normal

        Exclusion Criteria:

          -  Acute respiratory tract infection or pulmonary exacerbation requiring antibiotic
             intervention within 2 weeks of visit 1

          -  Any condition prohibiting the correct measurement of the NPD

          -  Active or passive smoking

          -  Planned treatment or treatment with another investigational drug or therapy within 1
             month prior to randomisation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patrick LEBECQUE, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cliniques universitaires St.Luc (Université catholique de Louvain)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Teresinha LEAL, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cliniques universitaires St.Luc ( Université Catholique de Louvain)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Anissa LEONARD, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cliniques universitaires St.Luc (Université Catholique de Louvain)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cliniques universitaires St. Luc</name>
      <address>
        <city>Brussels</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <results_reference>
    <citation>Dormer RL, Harris CM, Clark Z, Pereira MM, Doull IJ, Norez C, Becq F, McPherson MA. Sildenafil (Viagra) corrects DeltaF508-CFTR location in nasal epithelial cells from patients with cystic fibrosis. Thorax. 2005 Jan;60(1):55-9.</citation>
    <PMID>15618584</PMID>
  </results_reference>
  <results_reference>
    <citation>Lubamba B, Lecourt H, Lebacq J, Lebecque P, De Jonge H, Wallemacq P, Leal T. Preclinical evidence that sildenafil and vardenafil activate chloride transport in cystic fibrosis. Am J Respir Crit Care Med. 2008 Mar 1;177(5):506-15. Epub 2007 Nov 15.</citation>
    <PMID>18006891</PMID>
  </results_reference>
  <verification_date>June 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 26, 2009</study_first_submitted>
  <study_first_submitted_qc>October 26, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 27, 2009</study_first_posted>
  <last_update_submitted>June 6, 2012</last_update_submitted>
  <last_update_submitted_qc>June 6, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 7, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cliniques universitaires Saint-Luc- Université Catholique de Louvain</investigator_affiliation>
    <investigator_full_name>Anissa Léonard</investigator_full_name>
    <investigator_title>Dr</investigator_title>
  </responsible_party>
  <keyword>Cystic Fibrosis</keyword>
  <keyword>Vardenafil</keyword>
  <keyword>Nasal instillation</keyword>
  <keyword>Nasal Potential difference</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Cystic Fibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vardenafil Dihydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

